|Articles|July 22, 2016

EMA Seeks to Revise Guidance on First-In-Human Trials

July 22, 2016

The European Medicines Agency (EMA) is proposing changes to the current guidelines on first-in-human clinical trials to improve risk-based strategies. This proposal was made with cooperation from the European Commission and the Member States of the European Union (EU).

Read the full release here

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

EMA Seeks to Revise Guidance on First-In-Human Trials

Related Content

Evogene Announces AI-Powered Small Molecule Discovery Focused Partnership with Blavatnik Center for Drug Discovery at Tel Aviv University

“AI as Reinvention”: Transforming the Business of Medicine

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Additive Manufacturing's Application in Pharma and Biotech

Trending on PharmExec

Novartis to Layoff 322 NJ Employees: Report

Launch is Just the Beginning: Rare Disease Care Requires Durability

Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement

“AI as Reinvention”: Transforming the Business of Medicine

FDA Approves Ennumo to Decrease Incidence of Infection by Febrile Neutropenia